Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Genes and apps could limit health check invites
Fri August 16th - The NHS could seek to cut the cost of screening middle-aged adults by using apps and AI, it was announced today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Fluorescent marker could help brain cancer surgery

Monday November 5th, 2018

Surgeons have safely removed brain tumour cells with the help of a chemical that creates a fluorescent marker and highlights the cancer, a conference has heard.

A study, presented at the 2018 National Cancer Research Institute Cancer Conference in Glasgow, UK, yesterday (4 November 2018), was undertaken with people who had suspected glioma.

The study, led by Professor Colin Watts, chair of the Birmingham brain cancer programme at the University of Birmingham, UK, used 5-aminolevulinic acid (5-ALA), which glows pink when a light is shone on it.

Kathreena Kurian, a reader/associate professor in brain tumour research at the University of Bristol and consultant neuropathologist at North Bristol NHS Trust, UK, told delegates that using the fluorescent marker helped surgeons to distinguish the most aggressive cancer cells from other brain tissue.

Dr Kurian said: "We wanted to see if using a fluorescent marker could help surgeons objectively identify high-grade tumour cells during surgery, allowing them to remove as much cancer as possible while leaving normal brain tissue intact."

The study involved 113 patients at the Royal Liverpool Hospital, Kings College Hospital in London and Addenbrooke's Hospital, Cambridge, with suspected high-grade gliomas.

The patients, all aged between 23 and 77 years, were given a drink containing 5-ALA prior to surgery and 99 were able to be assessed for signs of fluorescence.

Surgeons used operating microscopes to help them look for fluorescent tissue while removing tumours from the patients' brains. The tissue they removed was sent to the pathology lab where scientists could confirm the accuracy of the surgeons' work.

Surgeons reported seeing fluorescence in 85 patients, 81 of whom were confirmed by pathologists to have high-grade disease. One was found to have low-grade disease and three could not be assessed.

No fluorescence was seen in 14 patients and only seven tumours could be subsequently evaluated by pathology. Low-grade disease was confirmed in all of them.

Professor Watts said: "Neurosurgeons need to be able to distinguish tumour tissue from other brain tissue, especially when the tumour contains fast-growing, high-grade cancer cells. This is the first prospective trial to show the benefits of using 5-ALA to improve the accuracy of diagnosing high-grade glioma during surgery. These results show that the marker is very good at indicating the presence and location of high-grade cancer cells.

"The advantage of this technique is that it may highlight more quickly high-grade disease within a tumour during neurosurgery. What this means is that more of the tumour can be removed more safely and with fewer complications, and that's better for the patient."

Kurian K et al. Abstract number 1765: 'Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker - result of the UK NCRI GALA-BIDD study.

Tags: Brain & Neurology | Cancer | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)